Healthcare of Ontario Pension Plan Trust Fund Invests $3.59 Million in Ralliant Corporation $RAL

Healthcare of Ontario Pension Plan Trust Fund bought a new stake in Ralliant Corporation (NYSE:RAL) in the 1st quarter, according to its most recent 13F filing with the SEC. The firm bought 86,400 shares of the company’s stock, valued at approximately $3,593,000.

A number of other hedge funds and other institutional investors have also added to or reduced their stakes in RAL. Viking Global Investors LP acquired a new position in Ralliant during the 2nd quarter worth approximately $257,200,000. State Street Corp acquired a new stake in Ralliant in the second quarter valued at approximately $213,096,000. Millennium Management LLC grew its stake in Ralliant by 172.4% in the fourth quarter. Millennium Management LLC now owns 4,973,001 shares of the company’s stock valued at $253,175,000 after acquiring an additional 3,147,660 shares during the period. Norges Bank bought a new stake in shares of Ralliant during the fourth quarter valued at approximately $124,687,000. Finally, Invesco Ltd. raised its position in shares of Ralliant by 90.1% during the third quarter. Invesco Ltd. now owns 3,871,690 shares of the company’s stock worth $169,309,000 after purchasing an additional 1,835,128 shares during the period.

Wall Street Analysts Forecast Growth

A number of brokerages recently issued reports on RAL. Citigroup increased their target price on Ralliant from $70.00 to $81.00 and gave the stock a “buy” rating in a report on Monday, July 13th. Barclays upped their price objective on shares of Ralliant from $52.00 to $67.00 and gave the stock an “overweight” rating in a report on Wednesday, May 13th. Royal Bank Of Canada raised their price objective on shares of Ralliant from $64.00 to $71.00 and gave the company a “sector perform” rating in a research note on Thursday, July 16th. Wall Street Zen cut shares of Ralliant from a “buy” rating to a “hold” rating in a report on Sunday, July 26th. Finally, Evercore began coverage on shares of Ralliant in a research report on Tuesday, June 9th. They set an “outperform” rating and a $80.00 target price for the company. One investment analyst has rated the stock with a Strong Buy rating, seven have assigned a Buy rating, three have given a Hold rating and one has assigned a Sell rating to the stock. According to data from MarketBeat, Ralliant currently has an average rating of “Moderate Buy” and a consensus target price of $73.00.

Ralliant Trading Down 0.0%

NYSE:RAL opened at $66.96 on Friday. The company has a debt-to-equity ratio of 0.73, a quick ratio of 1.05 and a current ratio of 1.61. The firm has a market cap of $7.49 billion and a price-to-earnings ratio of -6.12. Ralliant Corporation has a 52 week low of $37.27 and a 52 week high of $75.41. The firm has a 50-day moving average price of $67.12 and a two-hundred day moving average price of $54.26.

Ralliant (NYSE:RAL) last announced its earnings results on Thursday, July 30th. The company reported $0.68 earnings per share for the quarter, topping analysts’ consensus estimates of $0.63 by $0.05. Ralliant had a positive return on equity of 12.49% and a negative net margin of 58.55%.The firm had revenue of $567.80 million for the quarter. Ralliant has set its FY 2026 guidance at 2.760-2.900 EPS and its Q3 2026 guidance at 0.720-0.780 EPS. On average, equities analysts expect that Ralliant Corporation will post 2.64 earnings per share for the current fiscal year.

Ralliant Dividend Announcement

The firm also recently declared a quarterly dividend, which was paid on Tuesday, June 23rd. Investors of record on Monday, June 8th were issued a dividend of $0.05 per share. This represents a $0.20 dividend on an annualized basis and a yield of 0.3%. The ex-dividend date was Monday, June 8th. Ralliant’s dividend payout ratio (DPR) is -1.83%.

Trending Headlines about Ralliant

Here are the key news stories impacting Ralliant this week:

• Positive Sentiment: Ralliant’s second-quarter revenue increased 13% year over year to approximately $568 million, while adjusted EPS of $0.68 exceeded the $0.63 analyst consensus and edged up from $0.67 a year earlier. Adjusted EBITDA and net margins also improved. Ralliant Reports Second Quarter 2026 Results and Raises Full Year Guidance
• Positive Sentiment: The company raised its full-year 2026 adjusted EPS guidance to $2.76-$2.90, above the prior consensus estimate of $2.65, and projected revenue of roughly $2.25-$2.30 billion versus expectations near $2.2 billion. Ralliant forecasts 2026 revenue and productivity savings
• Positive Sentiment: Third-quarter guidance was also ahead of Wall Street expectations: adjusted EPS of $0.72-$0.78 versus $0.68 expected, and revenue of $570-$590 million versus approximately $556 million expected. The enterprise productivity program is expected to generate $50-$60 million in annualized savings by 2028. Ralliant Q2 earnings and revenues beat estimates
• Neutral Sentiment: Trading in RAL was temporarily halted under a limit-up/limit-down volatility pause, indicating heightened short-term price movement around the earnings release rather than a fundamental change in the business. Ralliant 2026 Q2 results presentation
• Negative Sentiment: GAAP results remain less compelling than adjusted figures: reported net earnings were $57 million, while the company continues to carry a negative net margin in some financial data, potentially limiting enthusiasm despite the earnings beat.

Ralliant Company Profile

Ralliant, Inc (NYSE: RAL) is a medical technology company focused on enabling point-of-care cell therapy solutions in the field of regenerative medicine. The company develops and markets systems that isolate, concentrate and store adipose-derived stromal vascular fraction (SVF) cells directly from a patient’s own fat tissue, facilitating same-day, autologous treatments without the need for extensive laboratory infrastructure.

The company’s core product portfolio includes proprietary device platforms and single-use processing kits engineered to streamline the workflow for clinicians.